426 related articles for article (PubMed ID: 36906663)
1. Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure.
Chang ML; Liaw YF
Drugs; 2023 Apr; 83(5):367-388. PubMed ID: 36906663
[TBL] [Abstract][Full Text] [Related]
2. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong GLH; Gane E; Lok ASF
J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2021 Nov; 5(11):1873-1887. PubMed ID: 34558823
[TBL] [Abstract][Full Text] [Related]
4. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
[TBL] [Abstract][Full Text] [Related]
5. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment.
Grudda T; Hwang HS; Taddese M; Quinn J; Sulkowski MS; Sterling RK; Balagopal A; Thio CL
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35797115
[TBL] [Abstract][Full Text] [Related]
6. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy.
Gao N; Guan G; Xu G; Wu H; Xie C; Mo Z; Deng H; Xiao S; Deng Z; Peng L; Lu F; Zhao Q; Gao Z
Aliment Pharmacol Ther; 2023 Nov; 58(10):1086-1098. PubMed ID: 37644711
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
[TBL] [Abstract][Full Text] [Related]
8. What will it take to cure hepatitis B?
Jeng WJ; Lok ASF
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
[TBL] [Abstract][Full Text] [Related]
9. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
10. State-of-the-art and emerging antivirals for chronic hepatitis B infection.
Papatheodoridi M; Papatheodoridis GV
Expert Opin Pharmacother; 2022 Dec; 23(18):1999-2012. PubMed ID: 36329612
[TBL] [Abstract][Full Text] [Related]
11. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
[TBL] [Abstract][Full Text] [Related]
12. Can we cure hepatitis B virus with novel direct-acting antivirals?
Martinez MG; Villeret F; Testoni B; Zoulim F
Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
[TBL] [Abstract][Full Text] [Related]
13. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
14. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
15. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
16. Getting to HBV cure: The promising paths forward.
Fung S; Choi HSJ; Gehring A; Janssen HLA
Hepatology; 2022 Jul; 76(1):233-250. PubMed ID: 34990029
[TBL] [Abstract][Full Text] [Related]
17. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.
Martinez MG; Boyd A; Combe E; Testoni B; Zoulim F
J Hepatol; 2021 Sep; 75(3):706-717. PubMed ID: 34051332
[TBL] [Abstract][Full Text] [Related]
18. The premise of capsid assembly modulators towards eliminating HBV persistence.
Bassit L; Amblard F; Patel D; Biteau N; Chen Z; Kasthuri M; Zhou S; Schinazi RF
Expert Opin Drug Discov; 2023; 18(9):1031-1041. PubMed ID: 37477111
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic strategies for chronic hepatitis B.
Phillips S; Jagatia R; Chokshi S
Virulence; 2022 Dec; 13(1):1111-1132. PubMed ID: 35763282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
